Cargando…

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study

SIMPLE SUMMARY: Patients suffering from metastasized melanoma can be treated with three different combinations of tablets (“targeted therapy”), with similar efficacy but different side effect profiles. When one of the combinations is not tolerated well, their physicians may switch to a different com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salzmann, Martin, Wald, Alexander, Stege, Henner, Loquai, Carmen, Zimmer, Lisa, Hayani, Kinan M., Heinzerling, Lucie, Gutzmer, Ralf, Enk, Alexander H., Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001327/ https://www.ncbi.nlm.nih.gov/pubmed/36900217 http://dx.doi.org/10.3390/cancers15051426

Ejemplares similares

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
por: Dörrie, Jan, et al.
Publicado: (2018)

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
por: Stege, Henner, et al.
Publicado: (2021)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
por: Salzmann, Martin, et al.
Publicado: (2020)

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
por: Hecht, Markus, et al.
Publicado: (2018)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
por: Salzmann, Martin, et al.
Publicado: (2022)

Acute low back pain as infusion-related reaction to monoclonal antibodies
por: Majenka, Pawel, et al.
Publicado: (2023)

Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAF(V600)
por: Skorokhod, Alexander, et al.
Publicado: (2013)

Correction: Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAF(V600)
por: Skorokhod, Alexander, et al.
Publicado: (2013)

S100 as Serum Tumor Marker in Advanced Uveal Melanoma
por: Salzmann, Martin, et al.
Publicado: (2023)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Heinzerling, L, et al.
Publicado: (2014)

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models
por: Eigentler, Thomas, et al.
Publicado: (2016)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
por: Munjapara, Vasu, et al.
Publicado: (2022)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Willingness to pay for a cure of low-risk melanoma patients in Germany
por: Augustin, Matthias, et al.
Publicado: (2018)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
por: Satzger, Imke, et al.
Publicado: (2015)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
por: Kähler, Katharina C., et al.
Publicado: (2018)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g2sfcd670sdh3fsu5n4v5v2u34